Patents Issued in October 18, 2022
  • RIP1 inhibitory compounds and methods for making and using the same
    Patent number: 11472782
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: October 18, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
  • Process for the preparation of glycidol
    Patent number: 11472783
    Abstract: This invention relates to a process for the preparation of glycidol from the thermal decarboxylation of glycerol carbonate. In one aspect, the present invention provides a process for the preparation of glycidol by thermal decarboxylation of glycerol carbonate, said process comprising the steps of: d) contacting liquid glycerol carbonate with a decarboxylation promotor, having a boiling point of at least 160° C. at atmospheric pressure and consisting essentially of an aliphatic mono-ol, an aliphatic polyol, or mixtures thereof, to form a liquid phase mixture; e) applying heat to the liquid phase mixture formed in step a) to induce thermal decarboxylation of the glycerol carbonate; and f) separating glycidol formed in step b) from the liquid phase mixture by evaporation of glycidol; and wherein the process does not comprise the use of a decarboxylation catalyst.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: October 18, 2022
    Assignee: Green Lizard Technologies Ltd.
    Inventors: Martin Atkins, Fergal Coleman, Sean Hardiman
  • Griseofulvin compound
    Patent number: 11472784
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: October 18, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Process for purification of tetrahydrocannabinolic- and cannabidiolic acid from plant material extract
    Patent number: 11472785
    Abstract: The present invention relates to a highly economic process for the purification of a cannabinoid acid, more specifically THCA or CBDA, from either a crude cannabis plant material or a cell culture of said cannabis plant, using ion exchange resins. The purified cannabinoid acid obtained may then be decarboxylated to yield the corresponding cannabinoid, i.e., THC or CBD, respectively.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: October 18, 2022
    Assignee: AL&AM Pharmachem Ltd.
    Inventor: Alexander Aizikovich
  • Methods for converting THC-rich cannabinoid mixtures into CBN-rich cannabinoid mixtures
    Patent number: 11472786
    Abstract: Disclosed herein is a method of converting a THC-rich cannabinoid mixture that comprises at least about 20% THC into a CBN-rich cannabinoid mixture that comprises at least about 2.0% CBN. The method comprises contacting the cannabinoid mixture with a benzoquinone reagent under reaction conditions comprising: (i) a reaction temperature that is within a target reaction-temperature range; and (ii) a reaction time that is within a target reaction-time range, such that at least a portion of the of the THC in the THC-rich cannabinoid mixture is converted into CBN.
    Type: Grant
    Filed: February 22, 2022
    Date of Patent: October 18, 2022
    Assignee: Canopy Growth Corporation
    Inventors: Christopher Adair, Mahmood Azizpoor Fard, Ben Geiling, Mohammadmehdi Haghdoost Manjili
  • Docosahexaenoic acid endocannabinoid epoxide derivative compositions
    Patent number: 11472787
    Abstract: The present disclosure provides novel compounds derived from docosahexaenoic acid endocannabinoid epoxides having anti-cancer, anti-inflammatory, anti-platelet aggregation and anti-angiogenic properties. Methods of synthesizing and using the compositions are also provided.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: October 18, 2022
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Aditi Das, Jahnabi Roy
  • Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases
    Patent number: 11472788
    Abstract: Disclosed herein are novel benzoimidazoles and pharmaceutical compositions comprising at least one such novel benzoimidazoles, processes for the preparation thereof, and the method for using the same in therapy. In particular, disclosed herein are certain novel benzoimidazoles that are useful for inhibiting indoleamine 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.
    Type: Grant
    Filed: November 24, 2018
    Date of Patent: October 18, 2022
    Assignee: BEIGENE, LTD.
    Inventors: Hexiang Wang, Yunhang Guo, Zhiwei Wang, Changyou Zhou
  • Bicyclic carboxamides and methods of use thereof
    Patent number: 11472789
    Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: October 18, 2022
    Assignee: TEMPEST THERAPEUTICS, INC.
    Inventors: Yalda Bravo, Austin Chih-Yu Chen, Jinyue Ding, Robert Gomez, Heather Lam, Joe Fred Nagamizo, Renata Marcella Oballa, David Andrew Powell, Tao Sheng
  • Dinitroxide biradical compounds as polarizing agents
    Patent number: 11472790
    Abstract: The present invention relates to novel organic dinitroxide biradical compounds and their use as polarizing agents, in particular, in the techniques of Nuclear Magnetic Resonance (NMR) of solids or liquid samples and medical imaging.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: October 18, 2022
    Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, University of Iceland
    Inventors: Gaël De Paepe, Frédéric Mentink-Vigier, Snorri Sigurdsson, Anil Jagtap
  • Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
    Patent number: 11472791
    Abstract: The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: October 18, 2022
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Jingwei Li, Zhenwu Li, Ding-Quan Qian, Liangxing Wu, Kaijiong Xiao, Meizhong Xu, Jeffrey C. Yang, Wenqing Yao, Fenglei Zhang, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • Herbicidal mixtures
    Patent number: 11472792
    Abstract: The present invention provides a composition comprising (A) a compound of formula (I): wherein R1 is methyl or methoxy, R2 is hydrogen, methyl or ethoxy and A is a substituted heteroaryl group, or an N-oxide or salt form thereof, and (B) one or more further herbicides; as well as the use of such compositions in controlling plants or inhibiting plant growth.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: October 18, 2022
    Assignee: SYNGENTA CROP PROTECTION AG
    Inventors: Sally Elizabeth Russell, Sean Ng, James Alan Morris
  • Inhibitors of cysteine proteases and methods of use thereof
    Patent number: 11472793
    Abstract: The disclosure provides compounds, such as compounds of Formula II, with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
    Type: Grant
    Filed: February 4, 2022
    Date of Patent: October 18, 2022
    Assignee: Pardes Biosciences, Inc.
    Inventors: Lee D. Arnold, Andy Jennings, Walter Keung
  • Fused imidazole derivatives as IL-17 modulators
    Patent number: 11472794
    Abstract: A series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: October 18, 2022
    Assignee: UCB Biopharma SRL
    Inventors: Gareth Neil Brace, Rose Elizabeth Bardell-Cox, Gregory Foulkes, James Richard Frost, Helen Tracey Horsley, Elizabeth Pearl Jones, Fabien Claude Lecomte, James Thomas Reuberson, Monika-Sarah Elizabeth Dorothea Schulze, Richard David Taylor, Wei Tsung Yau, Zhaoning Zhu
  • 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
    Patent number: 11472795
    Abstract: The present invention relates to the 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3?-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) osteoporosis, (viii) cardiac hypertrophy, (ix) epilepsies and (x) neuropathic pain.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: October 18, 2022
    Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO—A.C.R.A.F. S.p.A.
    Inventors: Guido Furlotti, Claudia Cavarischia, Rosa Buonfiglio, Rosella Ombrato, Tommaso Iacoangeli
  • Cardiac sarcomere inhibitors
    Patent number: 11472796
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: October 18, 2022
    Assignee: CYTOKINETICS, INC.
    Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Wenyue Wang, Luke W. Ashcraft
  • Pesticidally active pyrazole derivatives
    Patent number: 11472797
    Abstract: Compounds of formula (I) as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control pests such as insect, acarine, mollusc and nematode pests.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: October 18, 2022
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Myriem El Qacemi, Aurelien Bigot, Andrew Edmunds, Julien Daniel Henri Gagnepain, André Jeanguenat, Thomas Pitterna, André Stoller, Davide Sabbadin, Regis Jean Georges Mondiere, Denis Gribkov
  • Compounds
    Patent number: 11472798
    Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.
    Type: Grant
    Filed: August 11, 2020
    Date of Patent: October 18, 2022
    Assignee: MISSION THERAPEUTICS LTD
    Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
  • Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
    Patent number: 11472799
    Abstract: Disclosed herein are serine threonine kinase (AKT) degradation/disruption compounds including an AKT ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of AKT-mediated diseases.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: October 18, 2022
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Jian Jin, Jing Liu, Ramon E. Parsons, Jia Xu, Xufen Yu
  • Organic compound and organic electroluminescent device comprising the same
    Patent number: 11472800
    Abstract: The present invention relates to a novel compound and an organic electroluminescent device including the same, and the compound according to the present invention is used in an organic material layer of an organic electroluminescent device, preferably an electron transport layer or a hole blocking layer, and may increase luminous efficiency, driving voltage and lifespan of the organic electroluminescent device.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: October 18, 2022
    Assignee: DOOSAN SOLUS CO., LTD.
    Inventors: Yong Hwan Lee, Jae Yi Sim
  • Crystalline forms of a FGFR inhibitor and processes for preparing the same
    Patent number: 11472801
    Abstract: The present disclosure relates to solid forms of N-{[2?-(2,6-difluoro-3,5-dimethoxyphenyl)-3?-oxo-2?,3?-dihydro-1?H-spiro[cyclopropane-1,4?-[2,7]naphthyridin]-6?-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: October 18, 2022
    Assignee: Incyte Corporation
    Inventors: Yongchun Pan, Chongsheng Eric Shi, Ming Tao, Wayne Han, Michael Xia, Dengjin Wang, Zhongjiang Jia, Jiacheng Zhou, Qun Li
  • Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
    Patent number: 11472802
    Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: October 18, 2022
    Assignee: Array BioPharma Inc.
    Inventors: Shane M. Walls, Li Ren, Ginelle A. Ramann, David A. Moreno, Andrew T. Metcalf, Elizabeth A. McFaddin, Gabrielle R. Kolakowski, James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Dean Kahn
  • 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
    Patent number: 11472803
    Abstract: The present application relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prevention of diseases, and to their use for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: October 18, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Henrik Teller, Alexandros Vakalopoulos, Melissa Boultadakis Arapinis, Alexander Straub, Hanna Tinel, Markus Brechmann, Matthias Beat Wittwer, Maximillian Andreas Kullmann, Till Freudenberger, Thomas Mondritzki, Tobias Marquardt
  • Compositions and methods for modulating hair growth
    Patent number: 11472804
    Abstract: The present disclosure relates to compounds that are capable of inhibiting the mitochondrial pyruvate carrier and promoting hair growth. The disclosure further relates to methods of promoting hair growth or treating conditions or disorders affecting hair growth, such as baldness or alopecia.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: October 18, 2022
    Assignee: The Regents of the University of California
    Inventors: William E. Lowry, Michael E. Jung, Heather R. Christofk, Xiaoguang Liu, Aimee Flores
  • Tricyclic compounds and their use as phosphodiesterase inhibitors
    Patent number: 11472805
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: October 18, 2022
    Assignee: PFIZER, INC.
    Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Ramalakshmi Yegna Chandrasekaran
  • Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors
    Patent number: 11472806
    Abstract: The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (Ia), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (Ia) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The compounds of formula (I) or (Ia) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: October 18, 2022
    Assignee: Domain Therapeutics
    Inventors: Anne-Laure Blayo, Thomas Catelain, Ismet Dorange, Cédric Genet, Baptiste Manteau, Stanislas Mayer, Stephan Schann
  • Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders
    Patent number: 11472807
    Abstract: Compound of formula (I) and its addition salts with pharmaceutically acceptable acids, and methods in which an effective amount of the compound or any pharmaceutically acceptable salt thereof is administered (as a medicament) to an individual in need thereof.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: October 18, 2022
    Assignees: COMMISSARIAT À L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, PERHA PHARMACEUTICALS
    Inventors: Aloïse Mabondzo, Charlotte Leuxe, Anne-Cécile Guyot, Nassima Oumata, Laurent Meijer
  • Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
    Patent number: 11472808
    Abstract: The present invention discloses substituted pyrrolo[1,2-c]pyrimidines, such as the compound which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: October 18, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yao-Ling Qiu, Xiaowen Peng, Wei Li, Xuri Gao, Jorden Kass, Byung-Chul Suh, Hui Cao, Jiajun Zhang, Yat Sun Or
  • Pyrazolo[1,5-a]pyrazin-4-yl derivatives
    Patent number: 11472809
    Abstract: There is a method for treating a psoriasis. A compound is administered in a therapeutically effective amount to a subject suffering therefrom. The compound has the structure or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: October 18, 2022
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Alpay Dermenci, Andrew Fensome, Brian Stephen Gerstenberger, Matthew Merrill Hayward, Dafydd Rhys Owen, Stephen Wayne Wright, Li Huang Xing, Xiaojing Yang
  • Imidazopyrazinones as PDE1 inhibitors
    Patent number: 11472810
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: October 18, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Karsten Juhl, Paulo Jorge Vieira Vital
  • Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist
    Patent number: 11472811
    Abstract: Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as an A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an A2A receptor antagonist.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: October 18, 2022
    Assignee: BEIGENE, LTD.
    Inventors: Guoliang Zhang, Changyou Zhou
  • Anti-cancer compounds targeting Ral GTPases and methods of using the same
    Patent number: 11472812
    Abstract: Methods of inhibiting the growth or metastasis of a cancer in a subject by inhibiting a Ral GTPase in the subject, and small molecule inhibitors of Ral GTPases useful in the methods of the invention. Pharmaceutical compositions containing the compounds of the invention, and methods of using the same.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: October 18, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Dan Theodorescu, Michael Fitzpatrick Wempe, David Ross, Chao Yan, Phillip Reigan
  • OX2R compounds
    Patent number: 11472813
    Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.
    Type: Grant
    Filed: September 27, 2020
    Date of Patent: October 18, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
  • Thienopyranones and furanopyranones as checkpoint inhibitors and modulators of anti-tumor immunity
    Patent number: 11472814
    Abstract: The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral, bacterial or fungal infection, atherosclerosis, Type 1 or 2 diabetes, obesity, inflammatory disease, and/or SYK-associated disorder including by modulating biological processes through the inhibition of SYK alone, or in combination with inhibition of one or more of PI3 kinase including PI3K-gamma isoform, BET bromodomain proteins, CDK 4/6, and checkpoint proteins, comprising the administration of a compound(s) of Formula I-V (or pharmaceutically acceptable salts thereof) as defined herein.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: October 18, 2022
    Assignee: SignalRx Pharmaceuticals, Inc.
    Inventors: Guillermo A. Morales, Joseph R. Garlich, Donald L. Durden
  • 1,4-diphenyl-1H-imidazole and 2,4-diphenylthiazole derivatives and preparation method therefor and use thereof
    Patent number: 11472815
    Abstract: Provided are 1,4-diphenyl-1H-imidazole and 2,4-diphenylthiazole derivatives having a structure represented by Formula I, a preparation method therefor and uses thereof: wherein R1 is any one of H, OH, and OCH3, R2 is any one of H, NO2, CH3, CF3, SO2CH3, COOCH3, or CONHCH3, R3 is any one of H, NO2, OCH3, or CF3, R4 is selected from H, CF3, or Cl, R5 is any one of H, Cl, CF3, or NHCH3, and R6 is any one of OCF3, CF3, or CN; V is either C or N, W is either CH or N, X is a C atom, Y is either CH or N, and Z is either CH or S. This compound can be used in preparation of anti-inflammatory adjuvants, TLR1 or TLR2 agonists, and anti-tumor agents and for regulating the activity activation level of TLR1 and TLR2 alkaline phosphatases in vitro and in vivo.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: October 18, 2022
    Assignee: SOUTHERN MEDICAL UNIVERSITY
    Inventors: Kui Cheng, Shuwen Liu, Gengzhen Zhu
  • Mcl-1 inhibitors and methods of use thereof
    Patent number: 11472816
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: October 18, 2022
    Assignee: AstraZeneca AB
    Inventors: Alexander Hird, Matthew Belmonte, Wenzhan Yang, Paul Secrist, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
  • Heterocyclic compound and organic light-emitting device comprising same
    Patent number: 11472817
    Abstract: The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting device comprising the same.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: October 18, 2022
    Assignee: LT MATERIALS CO., LTD.
    Inventors: Hyun-Ju La, Yu-Jin Heo, Won-Jang Jeong
  • Method for preparing modification polymerization initiator using continuous type reactor
    Patent number: 11472818
    Abstract: The present invention relates to a method for preparing a modification polymerization initiator with a high conversion ratio by minimizing side reactions. According to the method for preparing a modification polymerization initiator, a modification polymerization initiator which may easily initiate polymerization and provide a polymer with a functional group having affinity with a filler, may be prepared. Particularly, by performing the method using a continuous reactor, the production of by-products may be decreased, and as a result, the conversion ratio may be increased and a modification polymerization initiator with high purity may be prepared in a high yield.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 18, 2022
    Inventors: Jung Yong Lee, Dong Cheol Choe, Won Jae Lee, Jae Hoon Choe, Hyeon Hui Kim, Jong Young Choi
  • Method of treating cancer and other proliferative diseases with a gold(I) complex
    Patent number: 11472819
    Abstract: The invention is directed to a method of treatment of proliferative diseases or disorders such as cancer with gold(I) N-heterocyclic carbene (NHC) thiourea or substituted thiourea complexes, to the complexes per se and to therapeutic compositions containing these gold(I) based complexes.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: October 18, 2022
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Anvarhusein A. Isab, Adam A. A. Sulaiman
  • Organic molecules for optoelectronic devices
    Patent number: 11472820
    Abstract: An organic molecule having a structure of Formula I: for the application in optoelectronic devices.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: October 18, 2022
    Assignee: Samsung Display Co., Ltd.
    Inventors: Nico-Patrick Thöbes, Michael Danz, Damien Thirion, Alhama Arjona Esteban, Sebastian Dück, Angela Digennaro
  • Precursor compounds for atomic layer deposition (ALD) and chemical vapor deposition (CVD) and ALD/CVD process using the same
    Patent number: 11472821
    Abstract: The present invention relates to precursor compounds, and more particularly to nonpyrophoric precursor compounds suitable for use in thin film deposition through atomic layer deposition (ALD) or chemical vapor deposition (CVD), and to an ALD/CVD process using the same.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: October 18, 2022
    Assignee: HANSOL CHEMICAL. CO., LTD.
    Inventors: Jung-Wun Hwang, Ki-Yeung Mun, Jun-Won Lee, Kyu-Hyun Yeom, Jang-Hyeon Seok, Jung-Woo Park
  • Process for purifying acetoxysiloxanes
    Patent number: 11472822
    Abstract: Processes are described for purifying acidic, preferably superacidic, in particular trifluoromethanesulfonic acid-acidified, end-equilibrated acetoxysiloxanes, wherein the acidic, preferably superacidic, in particular trifluoromethanesulfonic acid-acidified, acetic anhydride-containing and optionally acetic acid-containing equilibrated, preferably end-equilibrated acetoxysiloxane, which is optionally dissolved in an inert solvent, is contacted with a base, the precipitate is filtered off thereafter and then the filtrate obtained is optionally purified by distillation.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: October 18, 2022
    Assignee: Evonik Operations GmbH
    Inventors: Wilfried Knott, Dagmar Windbiel, Horst Dudzik, Frauke Henning, Jan Caßens
  • Tetrazole silane compound, method for synthesizing said compound and use thereof
    Patent number: 11472823
    Abstract: The objectives of the present invention are: to provide a novel tetrazole silane compound, a method for synthesizing the same, and a silane coupling agent containing the tetrazole silane compound as a component; and to provide a surface treatment solution using the tetrazole silane compound, a method for surface treatment, and a method for adhering two different materials. The tetrazole silane compound according to the present invention is a compound represented by chemical formula (I). (In formula (I), X, R, and n are respectively the same as defined in the specification.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: October 18, 2022
    Assignee: SHIKOKU CHEMICALS CORPORATION
    Inventors: Noriaki Yamaji, Takayuki Murai, Miya Tanioka, Shusaku Iida, Masato Katsumura, Takahito Imamine, Masahiko Tsujino, Tomoya Mae, Hirohiko Hirao
  • Processes for preparing phosphorodiamidate morpholino oligomers
    Patent number: 11472824
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: October 18, 2022
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Baozhong Cai, Mitchell Martini, Katie Thomas, Ross Shimabuku
  • Real-time fluorescence imaging sensor for measuring glutathione in organelle and preparation method therefor
    Patent number: 11472825
    Abstract: The present invention relates to a real-time fluorescence imaging sensor for measuring glutathione in cell organelles and a method for fabricating the same. More specifically, the present invention relates to a novel compound for measuring glutathione in cell organelles, a method for preparing the novel compound, a real-time fluorescence imaging sensor for measuring glutathione in cell organelles, which comprises the novel compound, a method for fabricating the imaging sensor, and a method of measuring glutathione in cell organelles by use of the imaging sensor. When the composition comprising the compound according to the present invention is used, it can measure the antioxidant activity of the organelle mitochondria or Golgi apparatus in living cells, particularly stem cells, and can screen highly active stem cells based on the results obtained by measuring the antioxidant activity of the cell organelle.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: October 18, 2022
    Assignee: CELL2IN, INC.
    Inventors: Heun Soo Kang, Hye Mi Kim, Ji Eun Song, Myoung Jin Kim, Ki Hang Choi
  • Acyclic antivirals
    Patent number: 11472826
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HBV and/or HDV and/or HIV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 18, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Leonid Beigelman, Guangyi Wang, Minghong Zhong
  • Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues
    Patent number: 11472827
    Abstract: Tetradentate and octahedral metal complexes suitable for use as phosphorescent or delayed fluorescent and phosphorescent emitters in display and lighting applications.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: October 18, 2022
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jian Li, Guijie Li
  • Indacene based metallocene catalysts useful in the production of propylene polymers
    Patent number: 11472828
    Abstract: This invention relates homogeneous (typically solution) polymerization of propylene and optional olefin comonomer using metallocene catalyst compounds having a 1,5,6,7-tetrahydro-s-indacenyl moiety bridged to another indacenyl moiety or bridged to a substituted or unsubstituted indenyl moiety.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: October 18, 2022
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Jian Yang, Peijun Jiang
  • Hemicellulose processing method
    Patent number: 11472829
    Abstract: A method of processing an aqueous hemicellulosic stream containing lignin, comprising: (a) contacting an aqueous hemicellulosic stream containing lignin with a C3-8 alkyl alcohol at elevated temperature and acidic pH; (b) separating the reaction mixture obtained from step (a) into an aqueous phase containing hemicellulose-derived monosaccharide and an organic phase containing C3-8 alkyl alcohol; (c) concentrating the organic phase obtained from step (b) to remove at least some C3-8 alkyl alcohol; (d) treating the residue from step (c) with water or an aqueous medium having an alkaline pH; and (e) recovering C3-8 alkyl alcohol from the product of step (d).
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: October 18, 2022
    Assignee: SAPPI BIOTECH UK LIMITED
    Inventors: Edward Leslie Marshall, Alan Geoffrey Waite, David Peter Gibney
  • Cyclic dinucleotides as sting agonists
    Patent number: 11472830
    Abstract: Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: October 18, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Gilles Bignan, Peter Connolly, James Patrick Edwards, Stuart Emanuel, Sylvie Laquerre, Tianbao Lu, Mark Richter, Leonid Beigelman, Santhosh Kumar Thatikonda, Guangyi Wang, Minghong Zhong
  • Isotopically labeled bile acid derivatives
    Patent number: 11472831
    Abstract: The present application relates to isotopically labeled compounds of Formula I and methods of preparation and use thereof.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: October 18, 2022
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Gabriel Galvin, Kevin Schaab, Mathew Yanik